Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis

Table 2 5-Year Risk of Mortality in T2DM Patients with Cirrhosis

	Kaplan Meier Estimates
5-Year Survival Rate (%)	After Propensity Score Matching
5-Year Survival Rate (%)	Metformin	Metformin + SGLT2 I	P	HR (95%CI)
All	82.09	90.38	0.002	0.57 (0.41–0.81)
Subgroup ^a
Men	77.76	85.09	0.031	0.62 (0.4–0.96)
Women	84.52	94.8	< 0.01	0.46 (0.26–0.79)
White	80.08	93.96	< 0.001	0.39 (0.26–0.6)
Non-White	83.22	82.58	0.468	0.7 (0.27–1.85)
Hispanic	96.4	98.18	0.464	0.53 (0.1–2.94)
Non-Hispanic	75.58	93.83	< 0.001	0.4 (0.27–0.62)
Age 39–59	92.73	94.26	0.305	0.68 (0.32–1.43)
Age 60–80	82.66	88.62	0.011	0.58 (0.38–0.88)
MASH ^b	93.82	89.89	0.746	0.82 (0.25–2.7)

^a Type 2 diabetes mellitus (T2DM) patients with cirrhosis treated with metformin and sodium glucose cotransporter-2 inhibitors (SGLT2-I) were further divided into demographic subgroups and propensity score matched to the Metformin group by sex, race, ethnicity, and age groups
^b T2DM patients with non-alcoholic steatohepatitis (MASH) Cirrhosis treated with metformin and SGLT2-I were propensity score matched to T2DM patients with MASH cirrhosis on metformin (n = 2,820)
K-M probabilities values are percent free of death. P values indicate P Log-rank Test
CI, Confidence Interval; HR, Hazard Ratio; K-M, Kaplan Meier

ISSN: 1471-230X